Susquehanna International Group, LLP Amarin Corp Plcuk Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.57 - $0.8 $1,595 - $2,240	2,800 Added 1.88%	152,100 $95,000
Q2 2024 Aug 15, 2024	SELL	$0.63 - $1.07 $187,110 - $317,790	-297,000 Reduced 66.55%	149,300 $103,000
Q1 2024 May 07, 2024	BUY	$0.82 - $1.35 $169,658 - $279,315	206,900 Added 86.42%	446,300 $397,000
Q4 2023 Feb 14, 2024	SELL	$0.66 - $0.91 $38,676 - $53,326	-58,600 Reduced 19.66%	239,400 $208,000
Q3 2023 Nov 14, 2023	BUY	$0.85 - $1.43 $98,940 - $166,452	116,400 Added 64.1%	298,000 $274,000
Q2 2023 Aug 11, 2023	SELL	$1.12 - $1.49 $306,544 - $407,813	-273,700 Reduced 60.11%	181,600 $216,000
Q1 2023 May 16, 2023	BUY	$1.19 - $2.19 $406,147 - $747,447	341,300 Added 299.39%	455,300 $682,000
Q4 2022 Feb 14, 2023	BUY	$1.07 - $1.34 $39,376 - $49,312	36,800 Added 47.67%	114,000 $137,000
Q3 2022 Nov 14, 2022	SELL	$1.09 - $1.67 $68,452 - $104,876	-62,800 Reduced 44.86%	77,200 $84,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $3.69 $94,467 - $308,484	-83,600 Reduced 37.39%	140,000 $209,000
Q1 2022 May 16, 2022	SELL	$2.85 - $3.73 $670,035 - $876,923	-235,100 Reduced 51.25%	223,600 $736,000
Q4 2021 Feb 14, 2022	SELL	$3.24 - $5.18 $1.39 Million - $2.22 Million	-428,000 Reduced 48.27%	458,700 $1.55 Million
Q3 2021 Nov 15, 2021	BUY	$3.94 - $5.84 $1.22 Million - $1.82 Million	310,900 Added 53.99%	886,700 $4.52 Million
Q2 2021 Aug 11, 2021	SELL	$4.26 - $6.5 $1.26 Million - $1.93 Million	-296,300 Reduced 33.98%	575,800 $2.52 Million
Q1 2021 May 17, 2021	SELL	$5.03 - $8.8 $3.15 Million - $5.5 Million	-625,400 Reduced 41.76%	872,100 $5.42 Million
Q4 2020 Feb 16, 2021	BUY	$4.04 - $5.31 $575,700 - $756,675	142,500 Added 10.52%	1,497,500 $7.32 Million
Q3 2020 Nov 16, 2020	SELL	$3.64 - $7.76 $2.08 Million - $4.44 Million	-572,100 Reduced 29.69%	1,355,000 $5.71 Million
Q2 2020 Aug 14, 2020	SELL	$4.78 - $8.26 $14.5 Million - $25.1 Million	-3,043,700 Reduced 61.23%	1,927,100 $13.3 Million
Q1 2020 May 15, 2020	SELL	$4.0 - $21.53 $2.36 Million - $12.7 Million	-589,300 Reduced 10.6%	4,970,800 $19.9 Million
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $29.9 Million - $51.8 Million	2,145,700 Added 62.84%	5,560,100 $119 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $12.1 Million - $20.1 Million	869,200 Added 34.15%	3,414,400 $51.8 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $8.11 Million - $10.2 Million	-498,200 Reduced 16.37%	2,545,200 $49.4 Million
Q1 2019 May 15, 2019	SELL	$12.61 - $22.33 $31.8 Million - $56.3 Million	-2,520,700 Reduced 45.3%	3,043,400 $63.2 Million
Q4 2018 Feb 14, 2019	BUY	$12.41 - $22.98 $43.1 Million - $79.8 Million	3,471,100 Added 165.84%	5,564,100 $75.7 Million
Q3 2018 Nov 14, 2018	BUY	$2.45 - $16.27 $1.08 Million - $7.17 Million	440,500 Added 26.66%	2,093,000 $34.1 Million
Q2 2018 Aug 14, 2018	BUY	$2.68 - $3.48 $3.25 Million - $4.22 Million	1,213,100 Added 276.08%	1,652,500 $5.11 Million
Q1 2018 May 15, 2018	BUY	$2.99 - $4.44 $310,063 - $460,428	103,700 Added 30.89%	439,400 $1.32 Million
Q4 2017 Feb 14, 2018	SELL	$3.06 - $4.09 $667,998 - $892,847	-218,300 Reduced 39.4%	335,700 $1.35 Million
Q3 2017 Nov 20, 2017	BUY	$3.03 - $3.72 $1.68 Million - $2.06 Million	554,000	554,000 $1.94 Million

Others Institutions Holding AMRN

# of Institutions

176

Shares Held

65.1M

Call Options Held

258K

Put Options Held

98K

Sarissa Capital Management LP Greenwich, CT

24.9M
Shares

$12.4 Million
3.89% of portfolio
Kynam Capital Management, LP Princeton, NJ

12.4M
Shares

$6.21 Million
0.64% of portfolio
Eversept Partners, LP New York, NY

3.31M
Shares

$1.65 Million
0.16% of portfolio
Morgan Stanley New York, NY

2.55M
Shares

$1.27 Million
0.0% of portfolio
Scp Investment, LP

2.5M
Shares

$1.25 Million
1.16% of portfolio

View Full List

About AMARIN CORP PLCUK

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $202M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

More about AMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account